Antibacterial activity of Acinetobacter baumannii phage ϕAB2 endolysin (LysAB2) against both Gram-positive and Gram-negative bacteria

To investigate the nature and origin of the antibacterial activity of the lytic phage ϕAB2 toward Acinetobacter baumannii, we successfully isolated and characterized a novel phage lysozyme (endolysin) from ϕAB2 and named it LysAB2. To analyze antibacterial activity of LysAB2, the complete LysAB2 and two deletion derivatives were constructed, purified and characterized. Zymographic assays showed that only the intact LysAB2 could lyse the peptidoglycan of A. baumannii and the Staphylococcus aureus cell wall. Antibacterial analysis also showed that only the intact LysAB2 retained the complete bactericidal activity. When applied exogenously, LysAB2 exhibited a broad bacteriolytic activity against a number of Gram-negative and Gram-positive bacteria. Thermostability assays indicated that LysAB2 was stable at 20∼40°C. Its optimal pH was 6.0, and it was active from pH 4 to 8. Scanning electron microscopy revealed that exposure to 500 μg ml−1 LysAB2 for up to 60 min caused a remarkable modification of the cell shape of the bacteria. Treating bacteria with LysAB2 clearly enhanced permeation of the bacterial cytoplasmic membrane. These results indicate that LysAB2 is an effective lysozyme against bacteria, and they suggest that it is a good candidate for a therapeutic/disinfectant agent to control nosocomial infections caused by multiple drug-resistant bacteria.

[1]  Mark Johnson,et al.  NCBI BLAST: a better web interface , 2008, Nucleic Acids Res..

[2]  G. Volckaert,et al.  Genomic Analysis of Pseudomonas aeruginosa Phages LKD16 and LKA1: Establishment of the φKMV Subgroup within the T7 Supergroup , 2006, Journal of bacteriology.

[3]  M. Kakikawa,et al.  Molecular analysis of the lysis protein Lys encoded by Lactobacillus plantarum phage phig1e. , 2002, Gene.

[4]  P. Barrow,et al.  Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. , 1997, Trends in microbiology.

[5]  Harald Seifert,et al.  Acinetobacter baumannii: Emergence of a Successful Pathogen , 2008, Clinical Microbiology Reviews.

[6]  A. Monzingo,et al.  The refined crystal structure of an endochitinase from Hordeum vulgare L. seeds at 1.8 A resolution. , 1995, Journal of molecular biology.

[7]  H. Unno,et al.  Functional analysis of antibacterial activity of Bacillus amyloliquefaciens phage endolysin against Gram‐negative bacteria , 2001, FEBS letters.

[8]  L. Dijkshoorn,et al.  An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii , 2007, Nature Reviews Microbiology.

[9]  G. Volckaert,et al.  The genome of bacteriophage phiKMV, a T7-like virus infecting Pseudomonas aeruginosa. , 2003, Virology.

[10]  E Bergogne-Bérézin,et al.  Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features , 1996, Clinical microbiology reviews.

[11]  D. Higgins,et al.  T-Coffee: A novel method for fast and accurate multiple sequence alignment. , 2000, Journal of molecular biology.

[12]  Christoph Gille,et al.  STRAP: editor for STRuctural Alignments of Proteins , 2001, Bioinform..

[13]  N. Papo,et al.  Effects of the antimicrobial peptide temporin L on cell morphology, membrane permeability and viability of Escherichia coli. , 2004, The Biochemical journal.

[14]  Juan A Hermoso,et al.  Taking aim on bacterial pathogens: from phage therapy to enzybiotics. , 2007, Current opinion in microbiology.

[15]  A. Stintzi,et al.  Substrate specificities of tobacco chitinases. , 1998, The Plant journal : for cell and molecular biology.

[16]  Jan Borysowski,et al.  Bacteriophage Endolysins as a Novel Class of Antibacterial Agents , 2006, Experimental biology and medicine.

[17]  P. Immerzeel,et al.  N-acetylglucosamine and glucosamine-containing arabinogalactan proteins control somatic embryogenesis. , 2001, Plant physiology.

[18]  H. Unno,et al.  Bacillus amyloliquefaciens phage endolysin can enhance permeability of Pseudomonas aeruginosa outer membrane and induce cell lysis , 2004, Applied Microbiology and Biotechnology.

[19]  M. Hennig,et al.  Structure of jack bean chitinase. , 2000, Acta crystallographica. Section D, Biological crystallography.

[20]  M. Wróblewska.  Novel therapies of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp . infections: the state of the art , 2006, Archivum Immunologiae et Therapiae Experimentalis.

[21]  R. Bonomo,et al.  Global Challenge of Multidrug-Resistant Acinetobacter baumannii , 2007, Antimicrobial Agents and Chemotherapy.

[22]  Patil,et al.  Chitinolytic enzymes: an exploration. , 2000, Enzyme and microbial technology.

[23]  R. Stone.  Stalin's Forgotten Cure , 2002, Science.

[24]  Klaus Düring,et al.  The non‐enzymatic microbicidal activity of lysozymes , 1999, FEBS letters.

[25]  Geoffrey J. Barton,et al.  Jalview Version 2—a multiple sequence alignment editor and analysis workbench , 2009, Bioinform..

[26]  V. Fischetti,et al.  Therapeutic Effects of Bacteriophage Cpl-1 Lysin against Streptococcus pneumoniae Endocarditis in Rats , 2005, Antimicrobial Agents and Chemotherapy.

[27]  Edward M. Marcotte,et al.  Chitinases, chitosanases, and lysozymes can be divided into procaryotic and eucaryotic families sharing a conserved core , 1996, Nature Structural Biology.

[28]  N. Lin,et al.  Isolation and characterization of phi AB2: a novel bacteriophage of Acinetobacter baumannii. , 2010, Research in microbiology.

[29]  Liam J. McGuffin,et al.  The PSIPRED protein structure prediction server , 2000, Bioinform..

[30]  Narmada Thanki,et al.  CDD: specific functional annotation with the Conserved Domain Database , 2008, Nucleic Acids Res..

[31]  M. Vaara,et al.  Agents that increase the permeability of the outer membrane. , 1992, Microbiological reviews.

[32]  M. Wiweger,et al.  The first crystal structures of a family 19 class IV chitinase: the enzyme from Norway spruce , 2009, Plant Molecular Biology.